NIFTY  9,304.05  -0.41%
  SENSEX  29,918.40  -0.37%
 CURRENCY  Rs  64.25/$ 70.00/€, 83.21/£
  GOLD  28,893.00  0.43%
  SILVER  39,500.00  -0.43%
  DAX  12,438.00  -0.05%
  FTSE  7,203.94  -0.46%
  CAC  5,267.33  -0.07%
  HANG SENG  24,615.10  -0.34%
  NIKKEI  19,196.70  -0.29%
  Shanghai Composite  3,154.66  0.04%
  DOW JONES  20,940.50  -0.19%
  NASDAQ  6,047.61  -0.02%
  S&P 500  2,384.20  -0.19%
JUST IN - Anthony Lianzuala To Take Over As New Controller General Of Accounts KITEX GARMENTS - Board Approves Issue Of Bonus Shares In The Ratio Of 2:5

Continue To Look For Deals: Sun Pharma

Video:

Play this video

April 7: Sun Pharmaceutical, India's largest drugmaker by market value, has agreed to buy Ranbaxy in a $4 billion all-stock deal. Ranbaxy investors will get 0.8 share in Sun Pharma for every one of their shares. Agam Vakil shares details on the deal valuation and the shareholding pattern. Also, Bloomberg’s Ketaki Gokhale tells you what may happen to Ranbaxy's U.S. FDA woes post the deal.